Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | ANCA-Associated Vasculitis | Research

Evaluation of three scoring systems for predicting renal prognosis in antineutrophil cytoplasmic antibody-associated glomerulonephritis

Authors: Ruiqiang Wang, Xiaofeng Zhang, Xinfang Wang, Lin Chen, Qiuling Ma, Yajing Su, Jingwen Liu, Huihui Shi

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) is characterized by rapidly progressive glomerulonephritis, and timely initiation of treatment and evaluation is critical to prevent the progression of renal disease to end-stage renal disease (ESRD). The aim of this study was to evaluate predictive value of the renal risk score (RRS), Birmingham vasculitis activity score (BVAS), and renal vascular lesions (RVLs) score for renal prognosis in AAGN.

Methods

A retrospective analysis of ninety-four patients diagnosed with AAGN after renal biopsy was performed. The RRS, BVAS, and RVLs score were evaluated in relation to clinicopathologic features and renal prognosis. A receiver operating characteristic curve (ROC) was used to evaluate their renal prognostic value.

Results

The median follow-up time was 36 months. Thirty-eight patients progressed to ESRD. Survival analysis showed that renal prognosis worsened in the RRS group in order of low, medium, and high RRS (P < 0.05). Within the RVLs group, the renal prognosis of the groups with severe and moderate RVLs was worse than that of the group without RVLs (P = 0.012, P < 0.001), and the group with mild RVLs was close to that of the group without RVLs. ROC analysis showed that the AUC of RRS, BVAS, RVLs score, RVLs score combined with RRS (RVLs score & RRS, RR), RVLs score, and RRS combined with BVAS (RVLs score & RRS & BVAS, RRB) were 0.865, 0.624, 0.763, 0.910, and 0.942, respectively. The predictive power of RRB and RR was comparable and significantly better than the RRS, BVAS, and RVLs score. Based on simplicity and validity, RR was selected as the best predictor, and the relationship between RRS, RVLs score, and RR was calculated using a linear fit, resulting in the linear equation RR = -0.4766 + 0.1231 × RVLs score + 0.395 × RRS (P < 0.001).

Conclusions

In AAGN, the predictive power of RR for renal prognosis was superior to that of RRS, BVAS, and RVLs score. RR may serve as a new predictor of renal prognosis in AAGN.
Literature
1.
Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int. 2013;84(2):244–9.CrossRefPubMed
2.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefPubMed
3.
Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477–82.CrossRefPubMed
4.
Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177–88.CrossRefPubMed
5.
Saito M, Saito A, Abe F, Imaizumi C, Kaga H, Sawamura M, et al. Evaluation of a newly proposed renal risk score for Japanese patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol. 2022;26(8):760–9.CrossRefPubMed
6.
Lim JH, Han MH, Kim YJ, Jeon Y, Jung HY, Choi JY, et al. Histopathologic and clinicopathologic classifications of antineutrophil cytoplasmic antibody-associated glomerulonephritis: a validation study in a Korean cohort. Kidney Res Clin Pract. 2021;40(1):77–88.CrossRefPubMedPubMedCentral
7.
Chen Z, Lin L, Yang W, Chen N, Lin Y. Clinical characteristics and prognostic risk factors of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Int Immunopharmacol. 2020;87: 106819.CrossRefPubMed
8.
Wang R, Wu Y, Zhang X, et al. Clinicopathological characteristics and influencing factors of renal vascular lesions in anti-neutrophil cytoplasmic autoantibody-related renal vasculitis. Front Med. 2021;8: 710386.CrossRef
9.
Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant. 2017;32(2):248–53.PubMed
10.
11.
Ellis CL, Manno RL, Havill JP, et al. Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. BMC Nephrol. 2013;14:210.CrossRefPubMedPubMedCentral
12.
Mejia-Vilet JM, Martin-Nares E, Cano-Verduzco ML, Perez-Arias AA, Sedano-Montoya MA, Hinojosa-Azaola A. Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage. Clin Rheumatol. 2020;39(6):1935–43.CrossRefPubMed
13.
Villacorta J, Diaz-Crespo F, Guerrero C, Acevedo M, Cavero T, Fernandez-Juarez G. Long-term validation of the renal risk score for vasculitis in a Southern European population. Clin Kidney J. 2021;14(1):220–5.CrossRefPubMed
14.
Muso E, Endo T, Itabashi M, Kakita H, Iwasaki Y, Tateishi Y, et al. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol. 2013;17(5):659–62.CrossRefPubMed
15.
Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36.CrossRefPubMed
16.
Bai X, Guo Q, Lou Y, Nie P, Zhu Y, Li B, et al. Validation of the renal risk score for antineutrophil cytoplasmic antibody-associated glomerulonephritis in a Chinese population. Clin Rheumatol. 2021;40(12):5009–17.CrossRefPubMed
17.
de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8(10):1709–17.CrossRefPubMedPubMedCentral
18.
Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15(2):91–101.CrossRefPubMed
19.
20.
Katafuchi R, Vamvakas E, Neelakantappa K, Baldwin DS, Gallo GR. Microvascular disease and the progression of Iga nephropathy. Am J Kidney Dis. 1990;15(1):72–9.CrossRefPubMed
21.
Brabcova I, Tesar V, Honsova E, Lodererova A, Novotna E, Maixnerova D, et al. Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin a nephropathy progression. Nephrol Dial Transpl. 2011;26(2):573–9.CrossRef
22.
23.
Li PK, Ho KK, Szeto CC, et al. Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transpl. 2002;17(1):64–9.CrossRef
24.
Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93(3):568–79.CrossRefPubMed
25.
Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol. 2012;23(2):313–21.CrossRefPubMed
26.
Bajema IM, Hagen EC, Hermans J, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56(5):1751–8.CrossRefPubMed
27.
Tanna A, Guarino L, Tam FW, Rodriquez-Cubillo B, Levy JB, Cairns TD, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transpl. 2015;30(7):1185–92.CrossRef
28.
Mahr AD, Neogi T, Lavalley MP, Davis JC, Hoffman GS, McCune WJ, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener’s granulomatosis. Arthritis Rheum. 2008;59(6):884–91.CrossRefPubMedPubMedCentral
29.
Koike K, Fukami K, Yonemoto K, Iwatani R, Obata R, Ueda K, et al. A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis patients. Am J Nephrol. 2012;35(1):1–6.CrossRefPubMed
Metadata
Title
Evaluation of three scoring systems for predicting renal prognosis in antineutrophil cytoplasmic antibody-associated glomerulonephritis
Authors
Ruiqiang Wang
Xiaofeng Zhang
Xinfang Wang
Lin Chen
Qiuling Ma
Yajing Su
Jingwen Liu
Huihui Shi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01113-7

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

A study on endovascular treatment alone and bridging treatment for acute ischemic stroke

Research

Unusual grafts for living-donor liver transplantation

Research

Assessing vaginal wall indexes in premenopausal versus postmenopausal women by transrectal linear array high-frequency probe

Research

Hemodynamics combined with inflammatory indicators exploring relationships between ischemic stroke and symptomatic middle cerebral artery atherosclerotic stenosis

Research

Expression of microRNAs in leukocytes and serum of asbestosis patients

Research

The characteristics of extrachromosomal circular DNA in patients with end-stage renal disease